Nearly all postmenopausal women with early-stage HR+ breast cancer are treated with aromatase inhibitors. But these drugs can significantly compromise bone health and up the risk of fractures.

When one medicine doesn't help postmenopausal women with osteoporosis, doctors might recommend another. But if the second doesn't strengthen bones, what happens then? Taking them together might do the trick.

When breast cancer spreads to the bones, various drugs are available to control the disease. This class of drugs is called biophosphonates . A manufacturer-funded study suggests its drug is better than others.